Sample Preparation and Extraction in Small Sample Volumes Suitable for Pediatric Clinical Studies: Challenges, Advances, and Experiences of a Bioanalytical HPLC-MS/MS Method Validation Using Enalapril and Enalaprilat

Bjoern B. Burckhardt and Stephanie Laeer

Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine-University, 40225 Düsseldorf, Germany

Correspondence should be addressed to Bjoern B. Burckhardt; bjoern.burckhardt@uni-duesseldorf.de

Received 31 October 2014; Revised 5 February 2015; Accepted 5 February 2015

Academic Editor: Mohamed Abdel-Rehim

Copyright © 2015 B. B. Burckhardt and S. Laeer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In USA and Europe, medicines agencies force the development of child-appropriate medications and intend to increase the availability of information on the pediatric use. This asks for bioanalytical methods which are able to deal with small sample volumes as the trial-related blood lost is very restricted in children. Broadly used HPLC-MS/MS, being able to cope with small volumes, is susceptible to matrix effects. The latter restrains the precise drug quantification through, for example, causing signal suppression. Sophisticated sample preparation and purification utilizing solid-phase extraction was applied to reduce and control matrix effects. A scale-up from vacuum manifold to positive pressure manifold was conducted to meet the demands of high-throughput within a clinical setting. Faced challenges, advances, and experiences in solid-phase extraction are exemplarily presented on the basis of the bioanalytical method development and validation of low-volume samples (50 μL serum). Enalapril, enalaprilat, and benazepril served as sample drugs. The applied sample preparation and extraction successfully reduced the absolute and relative matrix effect to comply with international guidelines. Recoveries ranged from 77 to 104% for enalapril and from 93 to 118% for enalaprilat. The bioanalytical method comprising sample extraction by solid-phase extraction was fully validated according to FDA and EMA bioanalytical guidelines and was used in a Phase I study in 24 volunteers.

1. Introduction

For the last years both competent authorities, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), force the development of high quality child-appropriate medications and intend to improve the availability of information on the pediatric use. Due to the current lack of sufficient evidence-based pharmacotherapy in children, sophisticated clinical investigations in all pediatric age groups (particularly in neonates and infants) are required to overcome this drawback.

Unfortunately, most bioanalytical assays are not yet tailored to meet current ethical and analytical burdens for research in children. Although the blood sample volume for determination of drug concentration is limited to microliters, it is essential for a valuable determination in pediatric patients to keep the calibration range as broad as or even broader than in assays applied in adult studies. HPLC-MS/MS is a predestinated analytical technique that appears to be the most suitable to deal with small sample volumes obtained from children and is linked with high selectivity for the quantification of the analytes of interest in diverse biological matrices. However, both the chromatographic equipment and the mass spectrometer (MS) encounter problems caused by the matrix. For example, the lifetime of the HPLC column is reduced if the sample purification is insufficient. Additionally, the detection by MS is susceptible to matrix effects leading to ionization suppression or enhancement [1, 2]. The matrix has a profound impact and restrains a precise quantification especially at the lower concentration levels. This ends up in nonrobust methods that do not encompass the broadest calibration range possible.
Therefore, the role played by proper sample preparation and extraction is important to overcome and control the interference caused through the biological matrices. A sophisticated sample clean-up removes material that chromatographically interferes with the analyte, enables appropriate recoveries, and erases matrix compounds that shorten column lifetime and affect the detection by MS. Attempts to simplify sample preparation and to reduce the preparation time ended in the awareness that this process accounts for less accuracy and precision in quantification [3]. Biological fluids like plasma, serum, urine, and saliva present a varying composition of, for example, lipids, proteins, electrolytes, cells, coeluting metabolites, impurities, and degradation products. All of these components might interfere with the analyte of interest. To reduce this interference several methods had been developed in the past. Commonly used extraction techniques are protein precipitation (PPT), liquid/liquid extraction (LLE), and solid-phase extraction (SPE).

The purpose of the present work was to illustrate the importance of sample preparation exemplified by solid-phase extraction for the bioanalytical method development of low-volume assays for pediatric studies according to international agency guidelines. Using the method validation of enalapril, enalaprilat, and benazepril (internal standard), the encountered challenges and advances in sample preparation and solid-phase extraction as well as their effects on bioanalytical method validation of small volume samples were emphasized.

2. Methods

2.1. Material. The drug substances enalapril maleate CRS and enalaprilat dihydrate CRS (both European Pharmacopoeia Reference Standards) were purchased at the European Directorate for the Quality of Medicine & Healthcare (Strasbourg, France). Benazepril hydrochloride (≥ 98%, HPLC) and ethyl acetate (100% p.a.) were obtained from Sigma-Aldrich (Seelze, Germany). Methanol (HiPerSolv ChromaNorm HPLC grade), water (super gradient grade), and Formic acid (98–100% p.a.) was delivered by AppliChem (Gatersleben, Germany). Ammonium formate (99%, HPLC grade) was obtained from Fluka (Seelze, Germany). Blank human serum was provided by employees of the Institute of Clinical Pharmacy and Pharmacotherapy (Düsseldorf, Germany). Oasis 96-well plates (30 and 10 mg) and XBridge BEH C18 3.5 µm columns (3.0 mm × 150 mm) were obtained from Waters (Eschborn, Germany).

2.2. Preparation of Standard and Quality Control. Stock solutions of enalapril, enalaprilat, and benazepril (internal standard) were prepared at 0.10 mg/mL in methanol. These stock solutions were diluted with water to obtain working solutions with 10 µg/mL enalapril and enalaprilat as well as 166 ng/mL benazepril. For the calibration curve, blank serum was spiked with the analytes of interest and serially diluted.

The final calibration range of the mass spectrometry was 0.2–200 ng/mL enalapril and 0.18–180 ng/mL enalaprilat. Quality control (QC) samples were independently prepared at four concentration levels over the whole calibration range (LLOQ, low, medium, and ULOQ).

2.3. Sample Preparation, Extraction, and Scale-Up. Based on preliminary investigations on the degree of sample dilution prior to solid-phase extraction a dilution ratio of 1:23 using water led to a robust method with high recovery rates for all analytes of interest.

Solid-phase extraction was chosen for the extraction process of the biological fluid owing to the superior purification performance if compared to protein precipitation or liquid-liquid extraction. Based on the compound properties of enalapril and enalaprilat, strong mixed-mode ion exchangers were chosen as sorbent material for the purification. Both a cation exchanger that interacts with the carboxylic acid groups and an anion exchanger that binds with the amino group of all above-mentioned substances were evaluated on their applicability (Oasis MCX and MAX material). The SPE protocol included a conditioning step utilizing methanol to enable optimal wetting of the cavernous sorbent material. For the subsequent equilibration step, different pH values and acids in aqueous solutions were tested to warrant for best interaction conditions prior the aqueous sample was loaded into the cavity. Namely, 2% formic acid (v/v), 4% phosphoric acid (v/v), 0.2 N hydrochloric acid, and pure water were evaluated. To purify the sample as much as possible, washing steps from hydrophilic to lipophilic properties were evaluated (water, 2% formic acid, hydrochloric acid, methanol, isopropanol, acetone, ethyl acetate, and mixtures of the aforementioned). Elution was assessed by acidified methanol for MAX sorbent material and ammonium in methanol for MCX sorbent material. The kind of acid (or base), its concentration, and the corresponding elution volumes were investigated to obtain all analytes within one fraction by reducing the coeluted residual matrix to a minimum.

To meet current demands in sample throughput within a clinical study, the scale-up to offline positive pressure extraction was conducted. The switch to 96-well format came along with a changeover from vacuum extraction to positive pressure extraction. SPE-formats with higher amounts of SPE cavities per plate were commercially not available. For the critical steps of sample load, washing, and sample elution, the positive pressure was kept between 1 and 2 psi to warrant an intensive interaction between analyte and sorbent material as well as reproducible flow rate. Figure 1 illustrates the corresponding scale-up.

2.4. Chromatographic and Mass Spectrometric Conditions. The utilized modular HPLC system (Shimadzu Deutschland GmbH, Duisburg, Germany) consisted of a controller SCL-10Avp, two separate pumps LC-10ADvp, three-channel online degasser DGU-20A3 prominence, autosampler SIL-10ADvp, and a column oven (L-2300, VWR/Hitachi). For the separation of enalapril and enalaprilat an XBridge BEH C18 3.5 µm column (3.0 mm × 150 mm) was used. After injection
of 10 µL sample solution (methanol/water 40:60, v/v) the samples were separated under gradient conditions within 6-minute run time utilizing a methanol/water mixture (40:60, v/v) buffered with formic acid (1%, v/v) and ammonium formate (2 mM). The applied gradient started with 40% of methanol and increased stepwise after 0.5 minute to 60% and after 1 minute to 80%. Between 1 and 4 minutes the amount of methanol was continuously increased to 95% and reduced at 4.5 minutes to 40% of methanol again. It stayed at this level till the end of the run time. The flow rate was 0.4 mL/min and the column temperature was maintained at 50°C which resulted in a moderate back pressure of 125 bar. Triple-quadrupole tandem mass spectrometric detection was performed on an Applied Biosystems SCIEX API 2000 (Applied Biosystems/MDS SCIEX, Concord, Canada) with an electrospray ionization (ESI) interface running in positive ionization mode. The device screened the transitions channels 377.2 to 234.2 m/z (enalapril), 349.1 to 206.1 m/z (enalaprilat), and 425.3 to 351.2 m/z (benazepril) in multiple reaction monitoring (MRM) mode. All dwell times were set to 250 ms.

2.5. Validation. The bioanalytical method was fully validated according to current FDA and EMA bioanalytical guidelines as a quantitative confirmatory method in terms of linearity, specificity, accuracy, precision, recovery, matrix effect, and stability [4, 5]. A main focus during validation was on the extraction process. The latter was in particular validated on recovery of the extraction process and absolute plus relative matrix effect. Additionally, extraction process efficiency and interference caused by hyperlipidemic and hemolyzed samples were evaluated.

The ratio of peak area of serum spiked with analyte prior to solid-phase extraction (Areaₐ) with the peak area of blank serum spiked with analyte after the extraction (Areaₐ) yielded the recovery of the assay. Recovery was determined at four concentration levels with five replicates per level. Calculation was performed as follows:

\[
\text{RE} \% = \left( \frac{\text{Area}_A}{\text{Area}_B} \right) \times 100, \tag{1}
\]

where RE = recovery; Areaₐ = peak area of serum spiked with analyte prior to extraction; Areaₐ = peak area of blank serum spiked with analyte after the extraction.

Although the blood composition and pH value are strongly controlled and vary only slightly within a healthy subject, the overall consequence of all compounds in a biological sample matrix contributes to the matrix effect.
that alters the accurate and precise determination of the analyte of interest. Therefore, a suitable sample preparation and purification by SPE contributes extremely to a robust method being less-sensitive to the effect. Apart from broadly investigated absolute matrix effect, the investigation of the relative matrix effect appears in this context more relevant for precise and robust methods for the analysis of biological samples [2].

Calculation of the absolute matrix effect was conducted by calculating the ratio of the peak area of extracted human serum postspiked with analyte (\( \text{Area}_x \)) to the peak area of the analyte in the same concentration dissolved in mobile phase (\( \text{Area}_y \)). The absolute matrix effect was determined at four concentration levels with five replicates per level. The absolute matrix effect was calculated according to the equation by Matuszewski et al. [2]:

\[
\text{ME} [\%] = \left( \frac{\text{Area}_x}{\text{Area}_y} \right) \times 100, \tag{2}
\]

where ME = matrix effect; \( \text{Area}_x \) = detected peak area of extracted human serum postspiked with analyte; \( \text{Area}_y \) = detected peak area of dissolved analyte in mobile phase.

To distinguish between ion suppression and ion enhancement caused by the matrix, the calculated matrix effect was subtracted by 100. A value < 0 indicated ion suppression caused by the matrix while ion enhancement was present if the calculated value was > 0.

According to international guidelines, the absolute matrix effect should be evaluated but is not limited to a certain range. However, the applicant needs to be able to estimate the effect of the matrix on the assay's performance.

By contrast the European Medicines Agency provides a guidance mentioning fixed acceptance criteria for the relative matrix effect. The intersubject variability of the internal standard normalized relative matrix effect (IS-ME) of processed samples should be maximum 15% and is expressed as coefficient of variation (CV) [4]. The calculation of the latter was done by evaluation of the individual IS-normalized matrix effect being defined as the matrix factor of the analyte divided by the matrix factor of the IS. The matrix factor represents the ratio of the peak area in the presence and the absence of the matrix of the corresponding substance. The CV of the IS-normalized matrix effects of seven subjects was used to assess the relative ME. The relative matrix effect was evaluated at 0.39 ng/mL enalapril and 0.35 ng/mL enalaprilat (low concentration level) as well as at 200 ng/mL enalapril and 180 ng/mL enalaprilat (ULOQ). Per concentration level three replicates per subject were analysed:

\[
\text{IS-ME} [\%] = \left( \frac{\text{Peak area of analyte}_{\text{Presence of matrix}}}{\text{Peak area of analyte}_{\text{Absence of matrix}}} \right) \times \left( \frac{\text{Peak area of IS}_{\text{Presence of matrix}}}{\text{Peak area of IS}_{\text{Absence of matrix}}} \right)^{-1} \times 100, \tag{3}
\]

where IS-ME = internal standard normalized matrix effect.

To calculate the process efficiency of the solid-phase extraction the following equation by Taylor [1] was used:

\[
\text{PE} [\%] = \frac{\text{RE} [\%] \times (100 - \text{ME} [\%])}{100}, \tag{4}
\]

where PE = process efficiency; RE = recovery; ME = absolute matrix effect.

Further validation parameters, as listed in the international bioanalytical guidelines, were investigated as follows: linearity was evaluated by measuring freshly spiked human serum with enalapril and enalaprilat at 11 concentration levels. The bioanalytical method was evaluated on four different days by four different runs on accuracy and precision. Therefore, five independently prepared quality control samples were assessed on four concentration levels (enalapril: 0.2, 3.13, 25, and 200 ng/mL; enalaprilat: 0.18, 2.81, 22.5, and 180 ng/mL) per run. The precision was determined by ANOVA while the accuracy was described by percentage deviation of the mean value to the nominal values of each concentration level. A maximum deviation of ±15% (±20% at the LLOQ) was regarded as acceptable [4]. The selectivity was assessed by check for interaction caused by 7 human serum samples spiked with 11 common comediations. The long-term stability of the drugs was evaluated at −80 °C for at least 60 days, short-term stability conducted at 20 °C for 24 h, and autosampler stability for 24 h also at 20 °C. Additionally, the stability of the dried eluate after sample extraction was investigated at −20 °C for 24 h.

2.6. Application. The high-throughput approach was applied to a Phase I study in 24 healthy volunteers. Both urine and serum samples were withdrawn and analyzed after administration of 10 mg enalapril maleate. With focus on sample extraction, the applicability was evaluated on the time required to run the extraction, the occurrence of any clotting of the cavity during extraction, and the goodness of extraction by checking for any shift in retention time in samples of different volunteers and different sample conditions (e.g., hemolyzed samples).

3. Results and Discussion

3.1. Sample Preparation. Preliminary investigations on the degree of sample dilution had been shown to influence the extraction performance and accounted highly for a robust method with high recovery. Investigations on suitable sample dilution solvents (formic acid, phosphoric acid, hydrochloric acid, and water) and their mixing ratio with the sample itself were conducted. To determine the best suitable mixing ratio of acids or pure water, the ratio was varied between 1:1 and 1:23. The conducted investigations on the most appropriate dilution solvent showed that water is sufficient if high dilution factors were applied. By increasing the mixing ratio, the detected peak areas of enalapril and enalaprilat increased in parallel (Figure 2). A mixing ratio of 1:10 and 1:23 worked best with regard to sample recovery. The highest dilution ratio resulted in a total sample volume of about 1.2 mL. Owing to the maximum capacity of a cavity (~1.4 mL), a higher degree
of dilution is not recommended for routine. It increases the risk of carryover and rises the likelihood of sample mix-up as the sample solution needs to be pipetted at least in two parts into the cavity. The final composition of the diluted sample solution consisted of 50 µL serum being mixed with 5 µL benazepril working solution (IS) and 1100 µL water.

3.2. Sample Extraction. Specifically, if small biological sample volumes like in pediatric research require purification, the sample extraction plays a particular role. Commonly, protein precipitation (PPT), liquid/liquid extraction (LLE), and solid-phase extraction (SPE) are applied as extraction techniques. PPT is a fast and simple approach but works best only in protein-rich matrices such as whole blood, plasma, or serum. Nevertheless, the PPT is nonselective and does not remove matrix interferences other than proteins. In the investigations by Dams et al., PPT in combination with LC-MS/MS had the greatest matrix effect amongst the investigated purification approaches [3]. It is a useful and fast technique to optimize lifetime of the equipment but does not increase the analytical sensitivity which is important for low-volume LC-MS/MS assays. LLE allows separation of analytes of interest from proteins and other hydrophilic components, but if emulsions are formed, the separation of the organic solvent becomes difficult and might result in incomplete and various-analyte diffusion. Jessome and Volmer emphasized the cumbersome sample preparation by LLE and LC-MS/MS [6]. Especially the complex adjustment of the pH value for the transfer in the organic phase, extraction of highly polar substances and necessary multiple extraction steps are some challenges faced. In particular for high-throughput analytics—as it is useful in clinical study approaches—the LLE is not the first choice. Consequently, SPE was selected owing to its superior purification properties and flexibilities in extraction protocols to cope with diversity of analytes, purifications solvents, and biological fluids.

The selected drug combination (calculated log P values of enalapril: 2.5; enalaprilat: –0.9; benazepril: 3.5) carried the risk of improper binding to the sorbent due to Coulomb repulsion, losing hydrophilic analytes during too extensive and not well-balanced washing steps or by incomplete recovery of the more lipophilic compounds from the sorbent material during elution. All this may be attributed to low recovery or bad reproducibility which in turn narrows the calibration range, because especially lower concentrations might not conform to international guideline requirements. Available sorbent phases characterized by different interaction possibilities (van der Waals forces, ionic interaction, etc.) and different amounts of sorbent per cavity and the high flexibility in the SPE protocol on how intensive the purification of sample needs to be conducted represent some of many useful tools to overcome those drawbacks.

First extraction attempts were undertaken by utilizing Oasis MCX. This polymeric material is characterized by a strong cation exchanger (on sulfonic acid base) binding the carboxylic acids groups of the analytes of interest. However, purified samples showed a split peak for the selected transition of enalaprilat if determined by HPLC-MS/MS. The corresponding chromatograms revealed a peak occurring at an earlier retention time plus a second peak at the expected retention time of the compound (Figure 3).

The peak area and intensity of the first peak did not alter with different enalaprilat concentrations per sample and accounted therefore most likely for a residual serum matrix component. It was not possible to erase the peak neither by thought-out SPE nor by any number of different LC gradients or by different HPLC columns featured with opposed chromatographic properties (Atlantis T3, XBridge, and XSelect). The checks for contamination in mobile phase, autosampler, or solutions for SPE were additionally negative. At the lowest concentration level of the calibration curve, the first peak and the one of enalaprilat were comparable.

Figure 2: Comparison of mixing ratios of serum and water on resulting peak areas. The detected peak areas of enalapril (a) and enalaprilat (b) of purified serum samples are presented. The mixing ratio was varied between 1:1 and 1:23. Each determination was conducted by three independently prepared quality control samples. The mean and corresponding standard deviations are shown.
in shape, intensity, and peak area. This phenomenon carried the risk of less robustness if automated integration of the chromatogram is preferred. After also scanning for the second most intense transition of enalaprilat (349.1 → 206.1 m/z), clarity was brought to question as the first peak did not belong to enalaprilat. However, quantification with two transitions would have resulted in a higher LLOQ which was undesired as very low concentration levels are expected in the scheduled pediatric studies. Therefore, the sorbent material of the SPE was changed from cation exchanger to strong anion exchanger (MAX) and a new extraction protocol was developed. This brought success to the method, as the compound with the same transition as enalaprilat (349.1 → 206.1 m/z) could be detached by SPE and consequently the split peak was removed.

At this stage an excuse to an already established and fully validated extraction method for the same drug entities in urine (amongst others) is made to introduce another useful approach to purify the sample matrix, to reduce the relative matrix effects, and to meet the current EMA bioanalytical guideline [4]. A two-step solid-phase extraction by a weak anion exchanger followed by a strong cation exchanger significantly reduced the internal standard normalized matrix effect. The SPE extraction by Oasis MCX is compared to the two-step extraction by Oasis WAX + MCX. Each boxplot describes median, 25th, 75th percentile + 10th, and 90th percentile as whisker. $N = 9$ measurements per boxplot. Statistical analysis was performed by a Mann-Whitney-U test (two-tailed $P$ value).

At an early development stage of the extraction protocol in serum at which the extraction was not methodologically sound, we encountered some deviation in retention time when comparing the chromatograms of analyte solved in mobile phase to extracted analyte in serum (Figure 5). By increasing the amount of organic washing steps as well as the elution force of the used organic solvents (methanol, acetone, and ethyl acetate), this timely shift could be eliminated (Figure 5). Even the intensities and peak areas of both, the analyte in mobile phase and the analyte in purified serum, were finally comparable. This pointed out the gained high degree of sample purification and accounted for a very limited signal suppression by the residual matrix compound in the final extract. However, it illustrates that matrix effects not only affect the signal intensities of the mass spectrometer but can also alter the chromatographic performance. A comparable effect was recently published by Fang et al. [8]. Finally, the conducted investigations on the most appropriate elution solvent and its volume yielded 0.4 mL acidified methanol (2% formic acid, v/v). This elution step did not only served to elute the analytes of interest but also acted as a final step to fraction the analytes of interest and other interfering residual compounds. Hereby the choice and elution force of the solvent as well as the amount of solvent were investigated on their effect to attribute to a rugged, reliable, and selective protocol. As illustrated in Figure 6, there was a reciprocal relationship between the elution volume of acidified methanol and the detected peak areas of the analytes of interest. The obtained smaller peak areas—after the sorbent material was eluted with higher volumes of acidified methanol—might be explained by the fact that more interfering matrix was coeluted. The interference induced by the matrix led to ion suppression and smaller peak areas.
Figure 5: Multiple reaction monitoring scan chromatograms of enalapril, enalaprilat, and benazepril. The left graph illustrates the shift in retention time detected by comparing the analytes solved in mobile phase versus the analytes in purified matrix during first extraction attempts. Right graph shows the final chromatogram by comparing also the analytes in mobile phase versus analytes in purified serum. A timely shift in retention time was not detectable anymore. MRMs: $377.2 \rightarrow 234.2 \ m/z$ (enalapril), $349.1 \rightarrow 206.1 \ m/z$ (enalaprilat), and $425.3 \rightarrow 351.2 \ m/z$ (benazepril). The black line identifies the extracted serum samples and the grey line illustrates the drug substances dissolved in mobile phase. Cps: counts.

Figure 6: Effect of elution volume on peak area of the analytes of interest. The peak areas of enalapril (a), enalaprilat (b), and benazepril (c) after elution are presented with different volumes of 2% formic acid in methanol. Each determination was conducted by three independently prepared quality control samples. The mean and corresponding standard deviations are shown.
The final protocol for the serum method was destined to the following approach: the samples were extracted with Oasis MAX solid-phase extraction cartridges (10 mg, 1 mL)—a mixed mode, reverse-phase, and strong anion exchanger (quaternary amine base). The MAX 96-well plates chosen allowed for high sample throughput and were primed with 1 mL of formic acid in methanol (2%, v/v) followed by an equilibration step with 1 mL water. On the one hand, this aqueous step prior to sample load ensured that, for example, no denaturation and therefore clotting of sample matrix on the sorbent material happened. On the other hand, it offered the best interaction conditions with the sorbents. After the sample mixture was loaded into the cartridges and passed, the sorbent of the cartridges was washed by 1.0 mL of water, 1.0 mL of methanol-acetone mixture (60:40, v/v), 1.0 mL of ethyl acetate, and 500 μL of methanol. The increasing elution force of the investigated organic solvents was used mainly to wash out phospholipids that are known to be responsible for a large part of matrix effect in blood, serum, and plasma [9]. Finally the analytes were eluted from the cartridges once with 0.4 mL of formic acid in methanol (2%, v/v). The eluate was evaporated to dryness under a gentle stream of compressed air while shaking at 550 rpm at 40°C. The residue was reconstituted with 100 μL of methanol and water (40:60, v/v).

3.3. Scale-Up of Sample Preparation and Extraction to 96-Well Setting. For reproducible and high-quality solid-phase extraction (SPE) with a high run-to-run consistency as desired for clinical studies, the switch from single cartridges by vacuum extraction to 96-well positive pressure extraction was conducted. This scaling presented the highest possible offline scaling for the used SPE material. SPE-formats with higher amounts of SPE cavities per plate were commercially not available. The conventional vacuum manifold had the disadvantage of irreproducible analyte recoveries due to variable processing times in the columns. For the highest possible reproducibility during extraction, the controlled and appropriate flow rate is much more essential than applying either vacuum or positive pressure. However, the positive pressure manifold had the advantage of being equipped with a monitor to check for the flow rate of the liquid. Specifically the sample load, washing, and elution step are known to be the most sensitive and critical steps regarding the flow rate. The exact adjustment of the flow rate of the liquids was important to generate a well-balanced setting of high reproducibility, best extraction speed and duration of sample extraction.

The transfer from vacuum extraction to positive pressure not only enabled a semiautomated extraction but also highly increased the sample amount up to about thousand samples which can be purified per week by one laboratory technician. Since appropriate equipment for rapid and continuous drying was not commercially available, required equipment for the drying process was self-developed to suit best the laboratory preconditions and needs. Figure 1 is enclosed illustrating the scale-up from single cartridges using vacuum technique to the positive pressure extraction in 96-well format. As indicated in Figure 7, the scale-up is a mandatory step in method development if the assay will be applied to analyze hundreds or thousands of samples. In our positive pressure approach, it took about 2 hours from raw sample to sample preparation and extraction to the final sample solution ready to be determined by HPLC-MS/MS. In such a run, 96 samples could be prepared which required much more than one full working day (8 h) of one laboratory technician to prepare the same amount by the previously used vacuum manifold approach. The applied pressures of 1–3 psi were fully sufficient to ensure a continuous and appropriate flow rate of solvent/sample solution through the sorbent material. The scale-up enabled a nearly sixfold higher sample throughput.

3.4. Validation. The chosen calibration range of 0.2–200 ng/mL enalapril and 0.18–180 ng/mL enalaprilat, respectively, showed guideline-conforming linearity over all eleven concentration levels. Best fit of the linear regression was gained using the previous developmentscale. The results of the quality controlsamples were likewise within the guideline requirements of ±15% at all concentration levels.
Table 1: Results for recovery, absolute matrix effect, and process efficiency.

| Concentration [ng/mL] | Absolute matrix effect ± S.D. [%] | Mean recovery ± S.D. [%] | Mean process efficiency [%] |
|-----------------------|----------------------------------|--------------------------|----------------------------|
| Enalapril             |                                  |                          |                            |
| 0.195                 | −12.6 ± 11.9                     | 77.1 ± 0.7               | 67.4                       |
| 3.13                  | −8.9 ± 2.2                       | 103.5 ± 3.7              | 94.3                       |
| 25                    | −19.8 ± 4.4                      | 102.9 ± 6.3              | 77.6                       |
| 200                   | −175 ± 3.5                       | 92.0 ± 6.9               | 72.5                       |
| Enalaprilat           |                                  |                          |                            |
| 0.175                 | −1.5 ± 10.8                      | 99.9 ± 7.8               | 98.4                       |
| 2.81                  | 0.3 ± 3.7                        | 118.3 ± 4.6              | 118.7                      |
| 22.5                  | 10.5 ± 4.9                       | 102.4 ± 4.7              | 113.2                      |
| 180                   | 2.2 ± 3.5                        | 92.9 ± 9.2               | 94.9                       |
| Benazepril            |                                  |                          |                            |
| 25                    | −7.2 ± 2.8                       | 76.9 ± 2.3               | 71.3                       |

Data compiled as mean or mean ± standard deviation (S.D.).

Table 2: Relative matrix effect obtained in seven different human sources.

| Donor     | Enalapril 0.39 ng/mL | Enalapril 200 ng/mL | Enalaprilat 0.35 ng/mL | Enalaprilat 180 ng/mL |
|-----------|----------------------|---------------------|------------------------|-----------------------|
| Healthy adults 29–86 years old |                      |                     |                        |                       |
| ♂ Donor 1  | 106.7                | 96.8                | 162.5                  | 135.9                 |
| ♂ Donor 2  | 99.1                 | 95.7                | 122.1                  | 108.2                 |
| ♂ Donor 3  | 96.6                 | 96.6                | 120.9                  | 119.4                 |
| ♂ Donor 4  | 111.1                | 97.6                | 132.1                  | 126.6                 |
| ♂ Donor 5  | 107.2                | 97.8                | 121.0                  | 114.5                 |
| ♂ Donor 6  | 98.8                 | 94.5                | 123.1                  | 112.1                 |
| ♂ Donor 7  | 98.4                 | 92.8                | 114.4                  | 106.7                 |

Mean value of normalized relative ME ± S.D. [%] 102.6 ± 5.6 96.0 ± 1.8 128.0 ± 16.1 117.6 ± 10.5

CV [%] within donors 5.49 1.87 12.56 8.96

ME: matrix effect; S.D.: standard deviation; CV: coefficient of variation.

The relative matrix effects of the extracted serum samples at a low concentration level (0.39 ng/mL enalapril and 0.35 ng/mL enalaprilat, resp.) were 5.49% (CV) for enalapril and 12.56% for enalaprilat. At the ULOQ, coefficients of variation of 1.87% for enalapril and 8.96% for enalaprilat were evaluated for all seven different human sources. All findings complied with EMA bioanalytical guideline. Details are arranged in Table 2.

3.5. Application. For the Phase I study, in total approximately 1600 serum and 600 urinary samples were analyzed. No clotting of serum sample solution in any SPE cavity was noticed. A shift in the retention times of enalapril, enalaprilat, and benazepril in purified serum samples of 24 different sources was not detected during the analysis by HPLC-MS/MS and allowed for an automated integration. Furthermore, hemolyzed samples did not affect the extraction run negatively and showed no significant interference during analysis. The determined pharmacokinetic results of the Phase I study will be used to apply a new marketing authorization and remain therefore confidential. However, during sample determination 22 calibration curves in serum and 7 in urine were required to quantify the drug concentration in the corresponding samples. Obtained results of the calibration
curves on intra- and interrun accuracy proved the applicability of the established bioanalytical method comprising the good sample extraction and their suitable preparation. Figure 8 shows the accuracy results for the serum and urine calibration curves.

Furthermore, these tailored low-volume assays will be applied to pediatric Phase II and III studies. The available pediatric study investigating the pharmacokinetics of enalapril and its active metabolite enalaprilat in hypertensive children was published by Wells et al. using a radioimmunoassay [10]. They found mean concentrations between 2 and 25 ng/mL enalaprilat. Lloyd et al. reported enalaprilat concentration values between 0.9 and 12.7 ng/mL in children with heart failure [11]. Both reported ranges are covered by the linear range of the assay presented and confirm its applicability for pediatric research. The required sample volume of 50 μL serum for reliable determination appears additionally well suitable for clinical trials in all age groups, especially for neonates and newborns. The required sample volumes of published LC-tandem mass spectrometry assays on enalapril and enalaprilat range between 200 and 1000 μL blood [12–17].

4. Conclusion

Using the example validation of the low-volume bioanalytical method of enalapril and enalaprilat, pitfalls as well as improvements of the extraction protocol were shown. The aim of an accurate and precise low-volume method encompassing a broad calibration range with very low limits of quantification was only gained by complex extraction protocols. The calibration range of the established assay covers reported enalapril and enalaprilat concentrations in pediatric patients and proves its applicability for pediatric research. It was shown that the undertaken efforts for a sophisticated extraction protocol utilizing solid-phase extraction resulted in a high recovery and high reduction of matrix effect. Controlling the latter—amongst others—warranted for a valuable and reliable bioanalytical method in serum. It allowed successful validation of a low-volume bioanalytical HPLC-MS/MS method according the FDA and EMA bioanalytical guidelines. The applicability of the high-throughput approach was proven by a clinical study in 24 volunteers.

Conflict of Interests

There is no conflict of interests regarding the publication of this paper.

Acknowledgment

The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under Grant Agreement no. 602295 (LENA).

References

[1] P. J. Taylor, “Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray tandem mass spectrometry,” Clinical Biochemistry, vol. 38, no. 4, pp. 328–334, 2005.
[2] B. K. Matuszewski, M. L. Constanzer, and C. M. Chavez-Eng, “Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS,” Analytical Chemistry, vol. 75, no. 13, pp. 3019–3030, 2003.
[3] R. Dams, M. A. Huestis, W. E. Lambert, and C. M. Murphy, “Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid,” Journal of the American Society for Mass Spectrometry, vol. 14, no. 11, pp. 1290–1294, 2003.
[4] European Medicines Agency, *Guideline on Bioanalytical Method Validation: (EMEA/CHMP/EWP/192217/2009)*, 2012.

[5] Food and Drug Administration, *Guidance for Industry: Bioanalytical Method Validation*, U.S. Department of Health and Human Services, 2001.

[6] L. L. Jessome and D. A. Volmer, "Ion suppression: a major concern in mass spectrometry," *LC-GC North America*, vol. 24, no. 5, pp. 498–510, 2006.

[7] B. B. Burckhardt, J. Tins, and S. Laer, "Simultaneous quantitative and qualitative analysis of aliskiren, enalapril and its active metabolite enalaprilat in undiluted human urine utilizing LC-ESI-MS/MS," *Biomedical Chromatography*, vol. 28, no. 12, pp. 1679–1691, 2014.

[8] N. Fang, S. Yu, and M. J. Ronis, "Matrix effects break the LC behaviour rule for analytes in LC-MS/MS analysis of biological samples," *Experimental Biology and Medicine*. In press.

[9] E. Chambers, D. M. Wagrowski-Diehl, Z. Lu, and J. R. Mazzeo, "Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses," *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, vol. 852, no. 1-2, pp. 22–34, 2007.

[10] T. Wells, R. Rippley, R. Hogg et al., "The pharmacokinetics of enalapril in children and infants with hypertension," *Journal of Clinical Pharmacology*, vol. 41, no. 10, pp. 1064–1074, 2001.

[11] T. R. Lloyd, L. T. Mahoney, D. Knoedel, W. J. Marvin Jr., J. E. Robillard, and R. M. Lauer, "Orally administered enalapril for infants with congestive heart failure: a dose-finding study," *The Journal of Pediatrics*, vol. 114, no. 4, pp. 650–654, 1989.

[12] S. Ramusovic, G. Thielking, and S. Läer, "Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry," *Biomedical Chromatography*, vol. 26, no. 6, pp. 697–702, 2012.

[13] C. Ghosh, I. Jain, C. P. Shinde, and B. S. Chakraborty, "Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study," *Drug Testing and Analysis*, vol. 4, no. 2, pp. 94–103, 2012.

[14] Q. Gu, X. Chen, D. Zhong, and Y. Wang, "Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography-tandem mass spectrometry," *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, vol. 813, no. 1-2, pp. 337–342, 2004.

[15] D. M. Lima, I. M. Mundim, P. C. B. V. Jardim, T. S. V. Jardim, D. G. A. Diniz, and E. M. Lima, "A high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method using solid phase extraction for the simultaneous determination of plasma concentrations of enalapril and enalaprilate in hypertensive patients treated with different pharmaceutical formulations," *Therapeutic Drug Monitoring*, vol. 31, no. 6, pp. 710–716, 2009.

[16] S. Lu, K. Jiang, F. Qin, X. Lu, and F. Li, "Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 49, no. 1, pp. 163–167, 2009.

[17] N. M. Najib, N. Idkaidek, A. Adel et al., "Bioequivalence evaluation of two brands of enalapril 20 mg tablets (Narapril and Renitec) in healthy human volunteers," *Biopharmaceutics and Drug Disposition*, vol. 24, no. 7, pp. 315–320, 2003.